Nataro, JP, Kaper, JB. Diarrheagenic Escherichia coli
. Clinical Microbiology Reviews
1998; 11: 142–201.
Karmali, MA, et al.
The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli
. Journal of Infectious Diseases
2004; 189: 556–563.
Tarr, PI, Gordon, CA, Chandler, WL. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet
2005; 365: 1073–1086.
Zoja, C, Buelli, S, Morigi, M. Shiga toxin-associated hemolytic uremic syndrome: pathophysiology of endothelial dysfunction. Pediatric Nephrology
2010; 25: 2231–2240.
Noris, M, Remuzzi, G. Hemolytic uremic syndrome. Journal of the American Society of Nephrology
2005; 16: 1035–1050.
Karmali, MA, Gannon, V, Sargeant, JM. Verocytotoxin-producing Escherichia coli (VTEC). Veterinary Microbiology
2010; 140: 360–370.
Williams, DM, et al.
Acute kidney failure – a pediatric experience over 20 years. Archives of Pediatrics and Adolescent Medicine
2002; 156: 893–900.
Scallan, E, et al.
Foodborne illness acquired in the United States – major pathogens. Emerging Infectious Diseases
2011; 17: 7–15.
Gyles, CL. Shiga toxin-producing Escherichia coli: an overview. Journal of Animal Science
2007; 85: E45–E62.
Bettelheim, KA. The non-O157 Shiga-toxigenic (Verocytotoxigenic) Escherichia coli; under-rated pathogens. Critical Reviews in Microbiology
2007; 33: 67–87.
Gould, LH, et al.
Increased recognition of non-O157 shiga toxin-producing Escherichia coli infections in the United States during 2000–2010: epidemiologic features and comparison with E. coli O157 infections. Foodborne Pathogens and Disease
2013; 10: 453–460.
Lathrop, S, Edge, K, Bareta, J. Shiga toxin-producing Escherichia coli, New Mexico, USA, 2004–2007. Emerging Infectious Diseases
2009; 15: 1289–1291.
Crim, SM, et al.
Preliminary incidence and trends of infection with pathogens transmitted commonly through food – foodborne diseases active surveillance network, 10 U.S. sites, 2006–2014. Morbidity and Mortality Weekly Report
2015; 64: 495–499.
Gould, LH. Update: recommendations for diagnosis of shiga toxin-producing Escherichia coli infections by clinical laboratories. Clinical Microbiology Newsletter
2012; 34: 75–83.
United States Department of Health and Human Services. July 1st population estimates for 1990–2012 by Year, state, county, race (4 categories), ethnicity, sex and age (1-year or 5-year groups). (http://wonder.cdc.gov/bridged-race-v2012.html). Accessed in January 2014.
Anderson, RN, Rosenberg, HM. Age standardization of death rates: implementation of the year 2000 standard. National Vital Statistics System
1998; 43: 1–12.
Klein, RJ, Schoenborn, CA. Age adjustment using the 2000 projected U.S. population: United States Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics; 2001.
Hosmer DW, Lemeshow S. Model-building Strategies and Methods for Logistic Regression, 2nd edn. Hoboken, NJ: John Wiley & Sons Inc., 2000.
Stigi, KA, et al.
Laboratory practices and incidence of non-O157 shiga toxin-producing Escherichia coli infections. Emerging Infectious Diseases
2012; 18: 477–479.
Manning, SD, et al.
Surveillance for shiga toxin-producing Escherichia coli, Michigan, 2001–2005. Emerging Infectious Diseases
2007; 13: 318–321.
Gould, LH, et al.
Recommendations for diagnosis of shiga toxin-producing Escherichia coli infections by clinical laboratories. Morbidity and Mortality Weekly Report Recommendations and reports
2009; 58: 1–14.
Riley, LW, et al.
Hemorrhagic colitis associated with a rare Escherichia coli serotype. New England Journal of Medicine
1983; 308: 681–685.
Allue-Guardia, A, Martinez-Castillo, A, Muniesa, M. Persistence of infectious Shiga toxin-encoding bacteriophages after disinfection treatments. Applied and Environmental Microbiology
2014; 80: 2142–2149.
Hedican, EB, et al.
Characteristics of O157 versus non-O157 shiga toxin-producing Escherichia coli infections in Minnesota, 2000–2006. Clinical Infectious Diseases
2009; 49: 358–364.
Hadler, JL, et al.
Ten-year trends and risk factors for non-O157 shiga toxin-producing Escherichia coli found through shiga toxin testing, Connecticut, 2000–2009. Clinical Infectious Diseases
2011; 53: 269–276.
Preussel, K, et al.
Shiga toxin-producing Escherichia coli O157 is more likely to lead to hospitalization and death than non-O157 serogroups – except O104. PLoS ONE
Frank, C, et al.
Epidemic profile of shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany. New England Journal of Medicine
2011; 365: 1771–1780.
Voetsch, AC, et al.
Risk factors for sporadic shiga toxin-producing Escherichia coli O157 infections in FoodNet sites, 1999–2000. Epidemiology and Infection
2007; 135: 993–1000.
Mead, PS, et al.
Food-related illness and death in the United States. Emerging Infectious Diseases
1999; 5: 607–625.
Tauxe, R. Real burden and potential risks from foodborne infections: the value of multi-jurisdictional collaborations. Trends in Food Science and Technology
2008; 19: S18–S25.